The demand for Lipid-Lowering Agents in Egypt has been increasing steadily over the years.
Customer preferences: Egypt has a high prevalence of cardiovascular diseases, which has led to an increase in demand for Lipid-Lowering Agents. The majority of the population in Egypt prefers generic drugs due to their affordability. However, there is also a growing demand for branded drugs due to their perceived higher quality.
Trends in the market: The Lipid-Lowering Agents market in Egypt has been witnessing a shift towards combination drugs. Combination drugs are more effective in reducing cholesterol levels and are preferred by doctors to treat patients with high cholesterol levels. There is also a growing trend towards the use of non-statin drugs, such as PCSK9 inhibitors, which are more effective in reducing LDL cholesterol levels.
Local special circumstances: The healthcare system in Egypt is predominantly public, with limited access to healthcare for the general population. This has led to a rise in the number of private healthcare providers in the country. The government has also taken steps to increase the availability of Lipid-Lowering Agents by subsidizing the cost of these drugs.
Underlying macroeconomic factors: The Egyptian economy has been growing steadily over the years, with a focus on economic reforms and attracting foreign investments. This has led to an increase in disposable income and an improvement in the standard of living, which has resulted in an increase in demand for healthcare services. The Lipid-Lowering Agents market is expected to continue to grow in the coming years due to the rising prevalence of cardiovascular diseases and the increasing awareness about the importance of cholesterol management.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
